Sign In
Buy PHRRF
$0.0431
-0.0015 (-3.36%)
At Close: Jul 31, 2026
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
07:30am, Tuesday, 18'th Jul 2023
Toronto, Ontario--(Newsfile Corp. - July 18, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement yesterday with PharmaT
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson's Disease
09:03am, Wednesday, 06'th Oct 2021
“KET-LID” trial to evaluate ketamine's safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease “KET-LID” trial to evaluate ketamine's safety an
PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors
05:41pm, Tuesday, 28'th Sep 2021
TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to ann
PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors
08:00am, Friday, 24'th Sep 2021
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
07:00am, Monday, 13'th Sep 2021
TORONTO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to pr
PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08:51am, Thursday, 09'th Sep 2021
TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to an
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
05:37pm, Tuesday, 07'th Sep 2021
TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released b
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease
08:05am, Tuesday, 25'th May 2021
TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to anno
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher's Ketamine Programs
09:28am, Thursday, 20'th May 2021
TORONTO, May 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce the appoin
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease
07:59am, Monday, 17'th May 2021
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U
Newscope Announces Name Change to PharmaTher Holdings Ltd.
11:29am, Tuesday, 13'th Apr 2021
TORONTO, April 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that, further to the news release dated April 8, 2021, it
Newscope Announces Name Change
10:40am, Thursday, 08'th Apr 2021
TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that it has filed an alteration notice with BC Registry S
Newscope Capital Provides Dial-In Information for Special Meeting
02:01pm, Thursday, 01'st Apr 2021
TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) would like to provide the following dial-in information for the Company's upcomi
PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine
07:00am, Wednesday, 24'th Mar 2021
Represents a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders TORONTO, March 24, 2021 /PRNewswire/ - Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRR
World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor
09:15am, Tuesday, 16'th Mar 2021
Dr. Fava to advise on the clinical development of KETABET™ for Major Depressive Disorder Dr. Fava to advise on the clinical development of KETABET™ for Major Depressive Disorder
